ProteoNic Competitors

Looking for a trusted partner in the development of cell lines and manufacturing processes? Look no further. With over 20 years of experience, we specialize in high-yielding (5-14 g/L), GMP-ready, CHO, and HEK293 cell lines for the production of biologics, biosimilars, and gene therapy (AAV, Adenovirus). We have a proven track record of expressing all types of proteins, including bi-specific mAb, Fc-fusions, viral proteins, cytokines, and more. Our team of scientists is ready to support your project from start to finish, including process development, analytical methods, scale-up, tox-batches, and Master Cell Banking. At our company, we pride ourselves on our commitment to quality and customer satisfaction. Contact us today to see how we can help you achieve your goals and be your trusted partner in cell line and process development.

Integrys is the trusted source of imaging and video technology, rugged and embedded computers, engineering technology, and local support for the aerospace, defence, healthcare, manufacturing, public safety, telecom, and transportation industries. Over 50 years of experience gives us the strategic insight and technical savvy to help you succeed. Integrys is solution-focused. We work closely with leading manufacturers and actively seek ways to migrate proven transformational technology to new sectors. When it comes to the technologies that drive your business, we think ahead—so you don’t have to. We connect technology and innovation.

ARTES Biotechnology - globally active R&D company, specialized in developing biopharmaceutical production processes. Since 2002, ARTES has positioned itself as a valued partner for the pharmaceutical industry with proprietary expression systems and its competence from cell line development to manufacturing. We have positioned ourselves as a valued partner for the pharmaceutical industry with several technology transfers successfully implemented worldwide at clients' sites. Today, ARTES is a strong, well-established partner for the development of customer driven projects up to supply of pre-clinical material. In addition, we are developing own virus like particle (VLP) based vaccine candidates up to proof-of-concept in animals.